<b>Background/Objectives:</b> Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide well-established cardiovascular and renal benefits in heart failure (HF), type 2 diabetes (T2DM), and chronic kidney disease (CKD). The gene discussed is SLC5A2; the disease is heart failure.